Healthcare Focus Minnesota: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Focus Minnesota.

Press releases published on July 9, 2026

5 hours ago

New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management

Indeterminate GlobeNewswire

5 hours ago

UREVO Wins Red Dot Award 2026 for AI-Powered Wireless Recovery Boots, Recognized for Real-Time, AI-Adaptive Recovery

Indeterminate GlobeNewswire

5 hours ago

Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease

Indeterminate GlobeNewswire

6 hours ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Indeterminate GlobeNewswire

6 hours ago

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

Indeterminate GlobeNewswire

6 hours ago

Tris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine

Indeterminate GlobeNewswire

6 hours ago

Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care

Indeterminate GlobeNewswire

6 hours ago

What Clinicians Ask About Cartilage Regeneration Supplements: Answering the Clinical Questions Around Cartigenix HP®

Indeterminate GlobeNewswire

6 hours ago

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC

Indeterminate GlobeNewswire

6 hours ago

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Indeterminate GlobeNewswire

6 hours ago

NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner

Indeterminate GlobeNewswire

7 hours ago

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Indeterminate GlobeNewswire

10 hours ago

Cytosurge’s CellEDIT Conquers "Impossible" Genome Engineering Challenges

Indeterminate GlobeNewswire

12 hours ago

Dysport® est la première toxine botulinique à obtenir des résultats préliminaires positifs de phase III, à la fois dans la migraine épisodique et dans la migraine chronique.

Indeterminate GlobeNewswire

12 hours ago

Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

Indeterminate GlobeNewswire